Silence Therapeutics plc (SLNCF)

Silence Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	5.66	11.28	121.33	68.79	66.05	99.57
Short-Term Investments	64.42	73.84	26	-	19.67	-
Cash & Short-Term Investments	70.08	85.11	147.33	68.79	85.72	99.57
Cash Growth	-48.67%	-42.23%	114.18%	-19.75%	-13.91%	94.75%
Accounts Receivable	-	-	0.97	0.29	1.1	0.45
Other Receivables	22.22	24.61	25.94	23.69	19.79	11.04
Receivables	22.22	24.61	26.91	23.98	20.9	11.49
Prepaid Expenses	-	8.93	13.12	10.39	9.88	5.83
Other Current Assets	10.56	-	-	-	-	-
Total Current Assets	102.85	118.66	187.37	103.15	116.5	116.9
Property, Plant & Equipment	1.54	1.75	1.98	2.31	2.65	2.63
Long-Term Investments	-	-	-	-	0.34	0.41
Goodwill	10.36	10.62	9.39	9.98	9.65	10.28
Other Intangible Assets	0.25	0.29	0.31	0.36	0.39	0.03
Other Long-Term Assets	0.13	0.13	3.59	3.65	-	-
Total Assets	115.12	131.44	202.64	119.45	129.53	130.25

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	10.37	4.41	3.7	3.35	3.84	5.5
Accrued Expenses	-	8.91	12.05	11.72	10.67	8.85
Current Portion of Leases	0.09	0.09	0.12	0.23	0.54	0.19
Current Income Taxes Payable	-	0.04	0.65	0.47	0.71	0.25
Current Unearned Revenue	-	0.17	0.31	6.57	10.68	5.75
Total Current Liabilities	10.46	13.61	16.82	22.34	26.44	20.54
Long-Term Leases	0.04	0.07	-	0.12	-	-
Long-Term Unearned Revenue	55.22	55.45	51.79	75	76.49	98.17
Total Liabilities	65.72	69.14	68.61	97.46	102.93	118.71

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	10.29	10.29	10.29	8.85	6.49	6.08
Additional Paid-In Capital	620.01	617.56	609.56	455.77	273.11	249.6
Retained Earnings	-577.53	-562.57	-474.04	-431.89	-317.2	-301.91
Comprehensive Income & Other	-3.37	-2.98	-11.78	-10.73	64.19	57.78
Shareholders' Equity	49.4	62.3	134.02	21.99	26.59	11.54
Total Liabilities & Equity	115.12	131.44	202.64	119.45	129.53	130.25

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.14	0.16	0.12	0.35	0.54	0.19
Net Cash (Debt)	69.94	84.95	147.22	68.44	85.18	99.39
Net Cash Growth	-48.75%	-42.29%	115.09%	-19.65%	-14.29%	96.17%
Net Cash Per Share	1.48	1.80	3.18	1.85	2.65	3.35
Filing Date Shares Outstanding	47.23	47.23	47.22	46.5	35.95	29.93
Total Common Shares Outstanding	47.23	47.23	47.22	39.62	35.94	29.93
Working Capital	92.39	105.05	170.54	80.82	90.06	96.36
Book Value Per Share	1.05	1.32	2.84	0.56	0.74	0.39
Tangible Book Value	38.8	51.4	124.32	11.65	16.56	1.23
Tangible Book Value Per Share	0.82	1.09	2.63	0.29	0.46	0.04
Machinery	-	5.54	6.34	6.44	6.01	6.92

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 27, 2026

Data Sources Report a data error